Market Overview

Mid-Day Market Losers

Share:
Related PPHM
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab
New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma
Related QCOR
Mallinckrodt Is No Valeant-Philidor Situation, Morgan Stanley Says
There's A Reason Mallinckrodt Continues To Disclose A Protracted, Multi-Agency Probe Of Recently-Acquired Questcor Pharmaceuticals

Peregrine Pharmaceuticals (NASDAQ: PPHM) fell 76.81% to $1.25 at 1:00 pm. Peregrine Pharmaceuticals reported that it discovered major discrepancies in its Phase II trial data of bavituximab.

Questcor Pharmaceuticals (NASDAQ: QCOR) shares dipped 32.59% to $20.31. Analysts at ThinkEquity downgraded Questcor from “buy” to “hold.”

Daegis (NASDAQ: DAEG) dropped 19.08% to $1.40. Daegis' trailing-twelve-month ROE is -110.48%.

Dialogic (NASDAQ: DLGC) shares lost 15.44% to $2.71. Dialogic shares have dipped 72.56% over the past 52 weeks, while the S&P 500 index has gained 25.57% in the same period.

Posted-In: Mid-Day Market LosersNews Movers & Shakers Intraday Update Markets

 

Related Articles (DAEG + DLGC)

View Comments and Join the Discussion!

Get Benzinga's Newsletters